MBRX Moleculin Biotech, Inc.
Healthcare$2.46+0.00%OpenMarket Cap: $3.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
6.49
P/S
0.00
EV/EBITDA
0.25
DCF Value
$0.46
FCF Yield
-840.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
3114.2%
ROA
-129.8%
ROIC
-175.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-7.9M | $-12.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-7.5M | $15.6M | $— | — |
| FY null | $0.00 | -Infinity% | $-25.1M | $-33.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-5.9M | $-25.4M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-5.7M | $-7.6M | $— | — |
| Q1 null | $0.00 | NaN% | $-5.9M | $-6.4M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-6.6M | $-1.9M | $— | — |
| FY null | $0.00 | NaN% | $-26.6M | $-21.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-7.1M | $-10.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-6.2M | $-4.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-6.7M | $-5.0M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-8.9M | $-10.3M | $-128.25 | — |